News Releases

Pharming Group N.V. announces encouraging results from five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor) under a compassionate use program at the University Hospital Basel,

Pharming Group N.V. invites its shareholders to the 2020 Annual General Meeting (AGM) to be held at 14:00 CET on 20 May 2020 In accordance with the precautionary measures invoked by the Dutch government due to the extraordinary circumstances of the COVID-19 pandemic, and with the health and safety

Pharming Group N.V. announces the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine Agency (EMA), has adopted a positive opinion recommending an extension of the indication for RUCONEST® to the European Commission.

Pharming Group N.V. announces that it has been included in the Euronext Amsterdam Midkap index (AMX).

Pharming Group N.V. today announced that its Chief Financial Officer, Robin Wright, has decided (for family reasons) not to put himself up for re-election as a member of the Board of Management and thus as Chief Financial Officer at the upcoming General Meeting of Shareholders on 20 May 2020 and

Pharming Group N.V. today announced it has also received US Food and Drug Administration (FDA) approval of Pharming’s Prior Approval Supplement to add the new Netherlands production facility of starting material to the Biologics License Application (BLA) to support its lead product, RUCONEST®.

The Company will hold a conference call at 13.00 CET/07.00 EST today. Dial in details can be found on page 12 of the press release. Highlights:  Delivered revenue for the full year of €169.0 million (US$189.3 million) – an increase of 25% on 2018 Full year net profits were €36.2 million ($40.5

Pharming Group N.V. today announced it has received European Medicines Agency (EMA) approval of a Type II Variation for a new production facility for its lead product, RUCONEST®. Highlights: New production facility will significantly increase production capacity of RUCONEST® Product manufactured at

Pharming Group N.V. today announces the launch of an offering (the “Offering”) of approximately €125 million of senior unsecured convertible bonds due 2025 (the “Bonds”). The net proceeds of the issue of the Bonds will be used to redeem the approximately US$ 56 million loan with Orbimed Advisors in